202 related articles for article (PubMed ID: 15158805)
41. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
Gupta R; al-Said NH; Oreski B; Lown JW
Anticancer Drug Des; 1996 Jun; 11(4):325-38. PubMed ID: 8679055
[TBL] [Abstract][Full Text] [Related]
43. Synthesis of novel rhinacanthins and related anticancer naphthoquinone esters.
Kongkathip N; Luangkamin S; Kongkathip B; Sangma C; Grigg R; Kongsaeree P; Prabpai S; Pradidphol N; Piyaviriyagul S; Siripong P
J Med Chem; 2004 Aug; 47(18):4427-38. PubMed ID: 15317455
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.
Kamal A; Suresh P; Ramaiah MJ; Mallareddy A; Imthiajali S; Pushpavalli SN; Lavanya A; Pal-Bhadra M
Bioorg Med Chem; 2012 Mar; 20(6):2054-66. PubMed ID: 22364746
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
[TBL] [Abstract][Full Text] [Related]
46. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
47. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
48. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones.
Rhee HK; Park HJ; Lee SK; Lee CO; Choo HY
Bioorg Med Chem; 2007 Feb; 15(4):1651-8. PubMed ID: 17194596
[TBL] [Abstract][Full Text] [Related]
49. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and antitumor activity of 4-hydroxycoumarin derivatives.
Jung JC; Lee JH; Oh S; Lee JG; Park OS
Bioorg Med Chem Lett; 2004 Nov; 14(22):5527-31. PubMed ID: 15482917
[TBL] [Abstract][Full Text] [Related]
52. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
53. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and cytotoxic activity of novel derivatives of 4'-demethylepipodophyllotoxin.
Chen SW; Tian X; Tu YQ
Bioorg Med Chem Lett; 2004 Oct; 14(20):5063-6. PubMed ID: 15380199
[TBL] [Abstract][Full Text] [Related]
55. Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2'-chloro derivatives of etoposide and 4 beta-(arylamino)-4'-O-demethylpodophyllotoxins.
Hu H; Wang ZQ; Liu SY; Cheng YC; Lee KH
J Med Chem; 1992 Mar; 35(5):866-71. PubMed ID: 1312600
[TBL] [Abstract][Full Text] [Related]
56. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological evaluation of pyrroloiminoquinone derivatives.
Passarella D; Belinghieri F; Scarpellini M; Pratesi G; Zunino F; Gia OM; Via LD; Santoro G; Danieli B
Bioorg Med Chem; 2008 Mar; 16(5):2431-8. PubMed ID: 18077173
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
Karki R; Park C; Jun KY; Kadayat TM; Lee ES; Kwon Y
Eur J Med Chem; 2015 Jan; 90():360-78. PubMed ID: 25437622
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
Thapa P; Karki R; Yun M; Kadayat TM; Lee E; Kwon HB; Na Y; Cho WJ; Kim ND; Jeong BS; Kwon Y; Lee ES
Eur J Med Chem; 2012 Jun; 52():123-36. PubMed ID: 22503656
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
